4 days ago · ICER provides independent evaluations on the value of medical tests, treatments and delivery systems

Founded in 2006 and non-profit incorporated in 2013, ICER has become the nation’s non-partisan, independent, go-to-resource for objective evidence about the value of health care in the U.S. ICER’s appraisals of more than 100 drugs for more than 50 medical conditions, in addition to multiple devices and diagnostics, have demonstrated that ...

Find our most recent treatment assessments, or search from our archive of past assessments to find studies relating to treatments that matter to you.

ICER is driven by a mission to conduct evidence-based reviews of health care interventions, such as drug, devices and diagnostics, that help patients, doctors, and everyone else in the health care system know what works. ICER has a developed a Value Assessment Framework, which is the foundation of our work.

ICER provides an independent source of evidence review—free from financial conflicts of interest—to address these fundamental questions. Learn more.

Meet ICER's leadership team and staff. Read individual bios of members of the ICER team, from the president to researchers.

BOSTON, December 12, 2024 – The Institute for Clinical and Economic Review (ICER) today published its latest report on Unsupported Price Increases (UPI) of prescription drugs in the United States, highlighting the top 10 drugs with substantial net price increases in 2023. ICER determined that five of those drugs lacked adequate evidence to ...

Jan 22, 2025 · ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.

Dec 9, 2024 · diagnostic tests. In collaboration with patients, clinical experts, and other key stakeholders, ICER analyzes the available evidence on the benefits and risks of these interventions to measure their value and suggest fair prices. ICER also regularly reports on the barriers to care for patients and recommends solutions to ensure fair access to

ICER objectively evaluates the clinical and economic value of prescription drugs, medical tests, and other health care and health care delivery innovations. Learn more.